Paragon 28, Inc.

DB:7GQ Stock Report

Market Cap: €815.7m

Paragon 28 Valuation

Is 7GQ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 7GQ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 7GQ's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 7GQ's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 7GQ?

Key metric: As 7GQ is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 7GQ. This is calculated by dividing 7GQ's market cap by their current revenue.
What is 7GQ's PS Ratio?
PS Ratio3.5x
SalesUS$245.00m
Market CapUS$863.16m

Price to Sales Ratio vs Peers

How does 7GQ's PS Ratio compare to its peers?

The above table shows the PS ratio for 7GQ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.9x
EUZ Eckert & Ziegler
3.5x5.4%€960.1m
DRW3 Drägerwerk KGaA
0.2x4.2%€791.1m
SBS Stratec
1.5x7.7%€382.9m
AFX Carl Zeiss Meditec
2.4x8.0%€5.1b
7GQ Paragon 28
3.5x14.0%€863.2m

Price-To-Sales vs Peers: 7GQ is expensive based on its Price-To-Sales Ratio (3.5x) compared to the peer average (1.9x).

Price to Sales Ratio vs Industry

How does 7GQ's PS Ratio compare vs other companies in the DE Medical Equipment Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
DRW3 Drägerwerk KGaA
0.2x4.2%US$834.13m
PHH2 Paul Hartmann
0.3xn/aUS$789.28m
U4W0 Quotient
0.07xn/aUS$2.78m
MF6 MagForce
0.3xn/aUS$404.27k
No more companies available in this PS range
7GQ 3.5xIndustry Avg. 3.5xNo. of Companies4PS01.63.24.86.48+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 7GQ is expensive based on its Price-To-Sales Ratio (3.5x) compared to the European Medical Equipment industry average (3.5x).

Price to Sales Ratio vs Fair Ratio

What is 7GQ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

7GQ PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.5x
Fair PS Ratio3.8x

Price-To-Sales vs Fair Ratio: 7GQ is good value based on its Price-To-Sales Ratio (3.5x) compared to the estimated Fair Price-To-Sales Ratio (3.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 7GQ forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€9.35
€13.62
+45.6%
19.2%€19.00€11.40n/a6
Nov ’25€5.05
€13.00
+157.4%
24.3%€18.05€9.93n/a5
Oct ’25€5.85
€13.00
+122.2%
24.3%€18.05€9.93n/a5
Sep ’25€7.30
€13.28
+81.9%
22.1%€18.32€10.07n/a6
Aug ’25€7.00
€14.90
+112.9%
12.5%€18.63€13.04n/a6
Jul ’25€6.20
€14.90
+140.3%
12.5%€18.63€13.04n/a6
Jun ’25€6.95
€14.84
+113.5%
12.5%€18.55€12.98n/a6
May ’25€8.40
€16.61
+97.7%
13.6%€21.22€13.84n/a6
Apr ’25€11.40
€16.63
+45.8%
13.6%€21.25€13.86n/a6
Mar ’25€10.50
€16.61
+58.2%
13.6%€21.22€13.84n/a6
Feb ’25€11.60
€16.58
+43.0%
14.7%€21.00€13.69n/a6
Jan ’25€11.20
€15.75
+40.7%
21.0%€20.90€10.91n/a6
Dec ’24€10.00
€15.43
+54.3%
22.9%€21.09€11.00n/a6
Nov ’24€8.05
€23.66
+193.9%
27.0%€30.28€11.35€5.057
Oct ’24€11.50
€25.01
+117.5%
13.2%€29.33€21.08€5.857
Sep ’24€13.00
€25.01
+92.4%
13.2%€29.33€21.08€7.307
Aug ’24€15.90
€25.43
+60.0%
13.2%€29.83€21.44€7.007
Jul ’24€16.10
€25.43
+58.0%
13.2%€29.83€21.44€6.207
Jun ’24€16.60
€25.43
+53.2%
13.2%€29.83€21.44€6.957
May ’24€16.50
€25.12
+52.3%
13.2%€29.46€21.18€8.407
Apr ’24€15.20
€26.33
+73.3%
12.2%€30.10€22.57€11.406
Mar ’24€16.30
€25.71
+57.7%
12.2%€29.39€22.04€10.506
Feb ’24€17.00
€25.71
+51.2%
12.2%€29.39€22.04€11.606
Jan ’24€18.10
€26.21
+44.8%
12.2%€29.95€22.46€11.206
Dec ’23€19.30
€26.26
+36.1%
11.7%€30.89€23.17€10.005
Nov ’23€19.90
€26.15
+31.4%
9.8%€29.27€23.42€8.055

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

LNA Santé

€241.3m

Engages in the management and operation of health establishments.

2N3

€22.65

7D

-2.6%

1Y

18.6%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%

OrbusNeich Medical Group Holdings

HK$3.1b

An investment holding company, researches, develops, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People’s Republic of China, and the United States.

Q8T

HK$0.39

7D

-23.6%

1Y

-42.8%